These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24088156)

  • 1. Rooting out institutional corruption to manage inappropriate off-label drug use.
    Rodwin MA
    J Law Med Ethics; 2013; 41(3):654-64. PubMed ID: 24088156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA proposes new rules for off-label use of prescription drugs. Food and Drug Administration.
    Baker R
    BETA; 1998 Jul; ():8-9. PubMed ID: 11365570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Off-label prescribing: a call for heightened professional and government oversight.
    Dresser R; Frader J
    J Law Med Ethics; 2009; 37(3):476-86, 396. PubMed ID: 19723258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in children.
    Larkin I; Ang D; Avorn J; Kesselheim AS
    Health Aff (Millwood); 2014 Jun; 33(6):1014-23. PubMed ID: 24889951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulating off-label promotion of medications: has the pendulum swung too far?
    Hoffman MB; Yentzer BA; Feldman SR
    Skin Therapy Lett; 2015; 20(3):1-4. PubMed ID: 26382556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Commercial speech and off-label drug uses: what role for wide acceptance, general recognition and research incentives?
    Gilhooley M
    Am J Law Med; 2011; 37(2-3):258-77. PubMed ID: 21847881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off label drug promotion.
    Body Posit; 1998 Oct; 11(10):11. PubMed ID: 11365909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. View from the Nation's Capital. "Off-label" uses of approved drugs: limits on physicians' prescribing behavior.
    Appler WD; McMann GL
    J Clin Psychopharmacol; 1989 Oct; 9(5):368-70. PubMed ID: 2794099
    [No Abstract]   [Full Text] [Related]  

  • 9. Manufacturers' promotion of off-label drug use: implications for drug safety.
    Zieve A; Carome MA
    Expert Opin Drug Saf; 2016 Sep; 15(9):1149-51. PubMed ID: 27145440
    [No Abstract]   [Full Text] [Related]  

  • 10. Off-label use of medical products in radiation therapy: summary of the report of AAPM Task Group No. 121.
    Thomadsen BR; Heaton HT; Jani SK; Masten JP; Napolitano ME; Ouhib Z; Reft CS; Rivard MJ; Robin TT; Subramanian M; Suleiman OH
    Med Phys; 2010 May; 37(5):2300-11. PubMed ID: 20527564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. False Claims Act prosecution did not deter off-label drug use in the case of neurontin.
    Kesselheim AS; Darby D; Studdert DM; Glynn R; Levin R; Avorn J
    Health Aff (Millwood); 2011 Dec; 30(12):2318-27. PubMed ID: 22147859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.
    Chen DT; Wynia MK; Moloney RM; Alexander GC
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1094-100. PubMed ID: 19697444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Truth, Falsity, and Fraud: Off-Label Drug Settlements and the Future of the Civil False Claims Act.
    Krause JH
    Food Drug Law J; 2016; 71(3):401-40. PubMed ID: 29140064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Off-label prescriptions: how to identify them, frame them, announce them and monitor them in practice?
    Le Jeunne C; Billon N; Dandon A; ; Berdaï D; Adgibi Y; Bergmann JF; Bordet R; Carpentier A; Cohn E; Courcier S; Girault D; Goni S; Jolliet P; Liard F; Prot-Labarthe S; Simon T; Vernotte C; Westerloppe J
    Therapie; 2013; 68(4):225-39. PubMed ID: 23981260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospects for Enforcing Prohibitions on Off-Label Drug Promotion after United States v. Caronia: An Analysis of Litigated Cases.
    Liu S; Mello MM; Kesselheim AS
    J Health Polit Policy Law; 2021 Jun; 46(3):487-504. PubMed ID: 33647951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From off-label prescribing towards a new FDA.
    Tabarrok A
    Med Hypotheses; 2009 Jan; 72(1):11-3. PubMed ID: 18835103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Public financing for off-label use of drugs].
    Hammerman A; Lipschitz Y; Pliskin J; Greenberg D
    Harefuah; 2011 Feb; 150(2):163-7, 204. PubMed ID: 22164947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine.
    Wang B; Studdert DM; Sarpatwari A; Franklin JM; Landon J; Kesselheim AS
    PLoS One; 2017; 12(4):e0175313. PubMed ID: 28388667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off-label prescribing among office-based physicians.
    Radley DC; Finkelstein SN; Stafford RS
    Arch Intern Med; 2006 May; 166(9):1021-6. PubMed ID: 16682577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On-label and off-label drug use in the treatment of endometriosis.
    Quaas AM; Weedin EA; Hansen KR
    Fertil Steril; 2015 Mar; 103(3):612-25. PubMed ID: 25637479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.